For instance, sodium polyoxotungstate (POM-1), a classical small molecule CD39 inhibitor, has been reported to exhibit anti-tumor activity in various cancers, including multiple myeloma, acute myeloid leukemia, and bladder cancer [21,93,94]. Here, ENTPD1 is linked to urinary bladder carcinoma.